Search results
Results From The WOW.Com Content Network
Multiple sclerosis. Multiple sclerosis is an autoimmune disease, primarily mediated by T-cells. [15] The three main characteristics of MS are the formation of lesions in the central nervous system (also called plaques), inflammation, and the destruction of myelin sheaths of neurons.
Multiple sclerosis (MS) is an autoimmune disorder in which the immune system attacks and destroys the myelin sheath of nerve cells. It most commonly strikes people between the ages of 20 and 40.
In March 2017, ocrelizumab was approved in the United States for the treatment of primary progressive multiple sclerosis in adults. [22] [42] It is also used for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. [42]
In the second group, the myelin is inherently abnormal and undergoes degeneration. [6] The Poser criteria named this second group dysmyelinating diseases. [7] In the most well-known demyelinating disease, multiple sclerosis, evidence suggests that the body's immune system plays a significant role.
The process creates a thinner myelin sheath than normal, but it helps to protect the axon from further damage, from overall degeneration, and proves to increase conductance once again. The processes underlying remyelination are under investigation in the hope of finding treatments for demyelinating diseases, such as multiple sclerosis.
Multiple sclerosis is an autoimmune condition in which the body attacks myelin, the tissue that coats nerve fibers within the central nervous system, consisting of the brain and spinal cord ...
Demyelination is the loss of the myelin sheath insulating the nerves, and is the hallmark of some neurodegenerative autoimmune diseases, including multiple sclerosis, acute disseminated encephalomyelitis, neuromyelitis optica, transverse myelitis, chronic inflammatory demyelinating polyneuropathy, Guillain–Barré syndrome, central pontine ...
The Myelin Repair Foundation was founded in 2002 by Scott Johnson, a California entrepreneur. Johnson had been diagnosed with multiple sclerosis at the age of 20. When given his prognosis, he was told that an effective therapy would probably not be on the market for another 30 to 50 years.